5-[3,5-bis(trifluoromethyl)phenyl]-1,3-dimethyl-5,11-dihydro-1H-indeno-[2',1':5,6]pyrido[2,3-d]pyrimidine-2,3,6-trione | 1172613-03-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 5-[3,5-bis(trifluoromethyl)phenyl]-1,3-dimethyl-5,11-dihydro-1H-indeno-[2',1':5,6]pyrido[2,3-d]pyrimidine-2,3,6-trione
• 英文别名: FPIPP；2-[3,5-Bis(trifluoromethyl)phenyl]-5,7-dimethyl-5,7,9-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),3(8),11,13,15-pentaene-4,6,17-trione
• CAS: 1172613-03-4
• 化学式: C₂₄H₁₅F₆N₃O₃
• 分子量: 507.392
• InChiKey: QFCBBYVKBMLBPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  36
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1,3-茚满二酮 、 1,3-二甲基-6-氨基脲嘧啶 、 3,5-双三氟甲基苯甲醛 在 溶剂黄146 作用下， 反应 8.0h， 以65%的产率得到5-[3,5-bis(trifluoromethyl)phenyl]-1,3-dimethyl-5,11-dihydro-1H-indeno-[2',1':5,6]pyrido[2,3-d]pyrimidine-2,3,6-trione
  参考文献：
  名称：

  新型吡啶并嘧啶衍生物作为稳定毒素a（STa）诱导的cGMP合成的抑制剂

  摘要：

  合成了一系列吡啶并嘧啶衍生物，并在稳定的大肠杆菌毒素a的存在下评估了它们抑制环状核苷酸合成的能力。检查了围绕基本核心结构的结构活性关系，并给出了具有更好活性和潜在更好药理特性的例子。

  DOI：

  10.1016/j.bmcl.2009.04.024

文献信息

• Pyridopyrimidines derivatives compounds
  申请人：BIOLAB SANUS FARMACEUTICA LTDA

  公开号：US10280162B2

  公开（公告）日：2019-05-07

  The present invention describes new pyridopyrimidine derivatives compounds with structure represented by General Formula (I): or pharmaceutically acceptable salts thereof, or their mixtures (in any ratio), a pharmaceutical composition containing them, a method for using the new pyridopyrimidine derivatives compounds as inhibitor of the cyclic nucleotide synthesis or as inhibitor of the cAMP and cGMP synthesis, and their uses in the prophylactic and/or curative treatment of diarrhea, colitis and irritable bowel syndrome.

  本发明描述了结构由通式（I）表示的新型吡啶嘧啶衍生物化合物： 或其药学上可接受的盐，或它们的混合物（以任意比例），含有它们的药物组合物，使用新吡啶嘧啶衍生物化合物作为环核苷酸合成抑制剂或作为 cAMP 和 cGMP 合成抑制剂的方法，以及它们在腹泻、结肠炎和肠易激综合征的预防和/或治疗中的用途。
• NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS
  申请人：BIOLAB SANUS FARMACEUTICA LTDA

  公开号：US20180111926A2

  公开（公告）日：2018-04-26

  The present invention describes new pyridopyrimidine derivatives compounds with structure represented by General Formula (I): or pharmaceutically acceptable salts thereof, or their mixtures (in any ratio), a pharmaceutical composition containing them, a method for using the new pyridopyrimidine derivatives compounds as inhibitor of the cyclic nucleotide synthesis or as inhibitor of the cAMP and cGMP synthesis, and their uses in the prophylactic and/or curative treatment of diarrhea, colitis and irritable bowel syndrome.
• PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS
  申请人：BIOLAB SANUS FARMACEUTICA LTDA

  公开号：US20190218216A1

  公开（公告）日：2019-07-18

  The present invention describes new pyridopyrimidine derivatives compounds with structure represented by General Formula (I): or pharmaceutically acceptable salts thereof, or their mixtures (in any ratio), a pharmaceutical composition containing them, a method for using the new pyridopyrimidine derivatives compounds as inhibitor of the cyclic nucleotide synthesis or as inhibitor of the cAMP and cGMP synthesis, and their uses in the prophylactic and/or curative treatment of diarrhea, colitis and irritable bowel syndrome.
• Novel pyridopyrimidine derivatives as inhibitors of stable toxin a (STa) induced cGMP synthesis
  作者：Eric A. Tanifum、Alexander Y. Kots、Byung-Kwon Choi、Ferid Murad、Scott R. Gilbertson

  DOI：10.1016/j.bmcl.2009.04.024

  日期：2009.6

  A series of pyridopyrimidine derivatives were synthesized and evaluated for their ability to inhibit cyclic nucleotide synthesis in the presence of stable toxin a of Escherichia coli. The structure activity relationships around the basic core structure were examined and examples with better activity and potentially better pharmacological properties are presented.

  合成了一系列吡啶并嘧啶衍生物，并在稳定的大肠杆菌毒素a的存在下评估了它们抑制环状核苷酸合成的能力。检查了围绕基本核心结构的结构活性关系，并给出了具有更好活性和潜在更好药理特性的例子。